Scotiabank Reiterates Sector Outperform Rating on Tempest Therapeutics (TPST)

Scotiabank analyst George Farmer reiterated a Sector Outperform rating and $13.00 price target on Tempest Therapeutics (NASDAQ: TPST).

The analyst commented, "We view FDA aligning with TPST on the design of a registration Phase 3 trial in first-line hepatocellular carcinoma (HCC) as a pivotal de-risking event for the company. With this overhang behind the company and a trial start expected Q1/25, we see an increased ability to attract potential corporate partnership attention, although such would not be necessary if TPST is able to raise sufficient capital to go it alone as currently planned. The path to trial execution is quite fertile given what we would expect to be rapid enrollment in a space where no competing Phase 3 trials should exist by the time first patient is enrolled."

For an analyst ratings summary and ratings history on Tempest Therapeutics click here. For more ratings news on Tempest Therapeutics click here.

Shares of Tempest Therapeutics closed at $1.55 yesterday.

You May Also Be Interested In

• Jones Trading Starts Alterity Therapeutics (ATHE) at Buy
• Activist Ed Garden lauds new Fortune Brands CEO - Bloomberg
• FDA extends review of Praxis drug for rare epilepsy to December 2026